The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Gubarev K.K.
Burnazyan Federal Medical Biophysical Center of Federal Medical Biological Agency
Liver transplantation program at the Burnasyan Federal Biophysical Center: experience in 500 procedures
Journal: Pirogov Russian Journal of Surgery. 2024;(7): 45‑60
Views: 520
Downloaded: 13
To cite this article:
Voskanyan SE, Sushkov AI, Artemiev AI, et al. . Liver transplantation program at the Burnasyan Federal Biophysical Center: experience in 500 procedures. Pirogov Russian Journal of Surgery.
2024;(7):45‑60. (In Russ.)
https://doi.org/10.17116/hirurgia202407145
To analyze the features and outcomes of 500 liver transplantations in adults over a 12-year period.
The study included data on 500 liver transplantations between May 2010 and April 2023. We analyzed 483 adults who underwent transplantation and 438 candidates for this procedure. All data were obtained from local liver transplantation registry. Clinical outcomes were recorded as of June 1, 2023. Statistical analysis was performed using the Statistica 12 (StatSoft Inc., USA) and Jamovi version 2.3.21.0 software (Jamovi project).
Among 438 patients in the waiting list between January 2012 and May 2023, liver transplantation was performed in 198 (45%) cases including 27 (6%) transplantations from living-related donors and 37 (8%) procedures in other centers. There were 109 (25%) deaths. The 1- and 3-year survival rates were 81% (95% CI 76—85%) and 50% (95% CI 42—59%), respectively. Organs from deceased donors (n=134, 27%) and living-related donors (n=366, 73%) were used for transplantations. Redo transplantations were necessary in 21 (4%) cases. The median age of recipients was 45 years (range 18—72), median MELD-Na score — 16 (range 6—43). The most common indications for transplantation were viral cirrhosis (37%), cholestatic liver disease (16%), and hepatocellular carcinoma (14%). Monotherapy with calcineurin inhibitors was performed in 39% of cases, combination of calcineurin inhibitors and glucocorticoids, antimetabolites or mTOR inhibitors — 52%, three-component schemes — 8% of cases. Annual, 5- and 7-year survival rates of recipients after primary transplantation were 87% (95% CI: 84—90%), 79% (95% CI: 75—83%) and 75% (95% CI: 70—80%), respectively. In case of liver transplantation from living-related donors, these values were 89% (95% CI: 86—92%), 84% (95% CI: 80—88%) and 80% (95% CI: 75—85%), after transplantation from deceased donors — 81% (95% CI: 74—88%), 66% (95% CI: 57—76%) and 58% (95% CI: 45—72%), respectively.
Liver transplantation is highly effective for patients with diffuse and focal liver diseases. Living donors not only significantly improve availability of this technology, but also provide substantial advantages in outcomes compared to liver transplantation from deceased donors, reducing the likelihood of recipient mortality by 10% after one post-transplantation year and by more than 20% after five years.
Keywords:
Authors:
Gubarev K.K.
Burnazyan Federal Medical Biophysical Center of Federal Medical Biological Agency
Received:
15.11.2023
Accepted:
18.01.2024
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.